Commercialisation of optimisation technologies and the nursing care and healthcare fields
First written in FY2016. 14 of 16 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-26.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Together with external experts, we are pursuing a demonstration project for expansion into ASEAN using BLE Beacon, as well as development of a remote rehabilitation system using WalkCare.」
With a view to commercialising healthcare and new businesses, the scope of R&D initiatives has expanded to include development of a remote rehabilitation system using WalkCare. - FY2024AdvancedAnnual report
「In healthcare, we are pursuing joint research through industry-academia collaboration aimed at creating solutions that use AI to prevent age-related declines in mobility, as well as solutions that identify disease risks from damage to an individual's DNA and provide opportunities for countermeasures and prevention.」
With a view to commercialising healthcare operations, initiatives have expanded to joint research on preventing declines in mobility using AI and identifying and preventing disease risks based on DNA damage. - FY2023AdvancedAnnual report
「In addition, in healthcare, we are pursuing a wide range of research with a view to commercialisation, including research using AI and joint research aimed at creating solutions that identify disease risks from damage to an individual's DNA and provide opportunities for countermeasures and prevention.」
With a view to commercialising healthcare operations, the scope of initiatives has expanded from AI research to joint research on solutions that identify disease risks from DNA damage. - FY2022AdvancedAnnual report
「In addition, in healthcare, we are pursuing a wide range of research with a view to commercialisation, including research using AI and joint research aimed at creating solutions that identify disease risks from damage to an individual's DNA and provide opportunities for countermeasures and prevention.」
With a view to commercialising healthcare operations, the scope of initiatives has expanded from AI research to joint research on solutions that identify disease risks from DNA damage. - FY2022-Q2AdvancedAnnual report
「Initiation of the development of a new AI-based brain nuclear medicine testing method」
The company has provided a new concrete update on commercialising AI in healthcare, stating that it has begun developing a brain nuclear medicine testing method. - FY2022-Q1AdvancedAnnual report
「Against this backdrop, in addition to developing our own directional receiver, we further advanced initiatives toward creating a sustainable society, including participating in the Osaka DX Promotion Partners program supporting the digital transformation of small and medium-sized enterprises, filing a patent application relating to a “tertiary battery,” and participating in the development of an X-ray medical vehicle for the initial diagnosis outside hospitals of patients who test positive for COVID-19.」
In connection with commercialising businesses in the nursing care and healthcare fields, the report notes participation in the development of an X-ray medical vehicle for the initial diagnosis of patients who test positive for infectious diseases outside hospitals. - FY2021AdvancedAnnual report
「As part of these efforts, under the principle of taking risks, boldly pursuing new businesses and achieving sustainable growth, we invested to expand our business areas and move to the next stage, including through the strategic expansion of our SAP-related business and a business and capital alliance involving AI in the medical field.」
The commercialisation of AI businesses in healthcare has expanded from conventional medical image interpretation AI development to investments, including business and capital alliances. - FY2020-Q2AdvancedAnnual report
「“Development of a system to apply AI to medical image interpretation”」
As a specific initiative toward commercialising businesses in the nursing care and healthcare fields, the company advanced the development of a system applying AI to medical image interpretation. - FY2020-Q1AdvancedAnnual report
「We also began new initiatives with a view to the future, including the development of an “AI-based medical image interpretation system” with Micron.」
As part of its efforts to commercialise businesses in the nursing care and healthcare fields, the company began developing an AI-based medical image interpretation system with Micron. - FY2017RestatedAnnual report
「In the new business development area, we also worked to commercialise businesses centred on IoT and AI in the nursing care and healthcare fields.」
The company's efforts to commercialise IoT- and AI-centred businesses in the nursing care and healthcare fields have been reaffirmed. - FY2017-Q1AdvancedAnnual report
「Rakuwakai Healthcare System and UBIC, Inc. (renamed FRONTEO,Inc. effective 1 July) began joint research on the use of artificial intelligence in healthcare.」
The company began joint research on the use of artificial intelligence in healthcare with a view to commercialising businesses in the nursing care and healthcare fields. - FY2016First statedAnnual report
「In the new business development area, we worked toward commercialising optimisation technologies and businesses in the nursing care and healthcare fields.」
Optimisation technologies and the nursing care and healthcare fields are explicitly identified as targets for new business development.